Compare Stocks: SCNX, MNOV, DWTX, and HRTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DWTX Dogwood Therapeutics	$2.15 +8.6%	$1.57	$1.28 ▼ $9.50	$66.59M	1.71	45,810 shs	105,849 shs
HRTX Heron Therapeutics	$0.34 +0.7%	$0.43	$0.30 ▼ $1.58	$63.49M	1.65	2.63 million shs	1.76 million shs
MNOV MediciNova	$1.31	$1.34	$1.17 ▼ $1.96	$64.48M	0.63	32,636 shs	45,061 shs
SCNX Scienture	$0.47 +0.2%	$0.38	$0.24 ▼ $2.60	$18.89M	3.26	1.97 million shs	29.55 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DWTX Dogwood Therapeutics	+2.86%	+13.14%	+38.46%	+8.20%	-58.75%
HRTX Heron Therapeutics	-1.91%	-32.99%	-22.21%	-60.66%	-76.11%
MNOV MediciNova	-1.50%	-3.68%	-4.38%	-5.07%	+3.15%
SCNX Scienture	+3.33%	+24.77%	+19.54%	+15.38%	-79.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DWTX Dogwood Therapeutics	$2.15 +8.6%	$1.57	$1.28 ▼ $9.50	$66.59M	1.71	45,810 shs	105,849 shs
HRTX Heron Therapeutics	$0.34 +0.7%	$0.43	$0.30 ▼ $1.58	$63.49M	1.65	2.63 million shs	1.76 million shs
MNOV MediciNova	$1.31	$1.34	$1.17 ▼ $1.96	$64.48M	0.63	32,636 shs	45,061 shs
SCNX Scienture	$0.47 +0.2%	$0.38	$0.24 ▼ $2.60	$18.89M	3.26	1.97 million shs	29.55 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DWTX Dogwood Therapeutics	+2.86%	+13.14%	+38.46%	+8.20%	-58.75%
HRTX Heron Therapeutics	-1.91%	-32.99%	-22.21%	-60.66%	-76.11%
MNOV MediciNova	-1.50%	-3.68%	-4.38%	-5.07%	+3.15%
SCNX Scienture	+3.33%	+24.77%	+19.54%	+15.38%	-79.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DWTX Dogwood Therapeutics	2.00	Hold	$12.00	458.14% Upside
HRTX Heron Therapeutics	2.00	Hold	$2.00	494.00% Upside
MNOV MediciNova	2.67	Moderate Buy	$8.33	536.13% Upside
SCNX Scienture	2.00	Hold	$1.50	221.96% Upside

Current Analyst Ratings Breakdown

Latest SCNX, MNOV, DWTX, and HRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/3/2026	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/24/2026	DWTX Dogwood Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	HRTX Heron Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	SCNX Scienture	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/3/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$2.00
6/2/2026	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/19/2026	DWTX Dogwood Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
HRTX Heron Therapeutics	$154.90M	0.41	N/A	N/A	$0.07 per share	4.81
MNOV MediciNova	$410K	157.26	N/A	N/A	$0.85 per share	1.54
SCNX Scienture	$430K	44.02	N/A	N/A	$1.73 per share	0.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DWTX Dogwood Therapeutics	-$34.26M	-$10.60	N/A	N/A	N/A	N/A	-108.57%	-30.28%	N/A
HRTX Heron Therapeutics	-$20.19M	-$0.19	N/A	N/A	N/A	-22.52%	-265.11%	-10.02%	N/A
MNOV MediciNova	-$12M	-$0.23	N/A	N/A	N/A	-1,962.98%	-27.28%	-25.24%	N/A
SCNX Scienture	-$41.51M	-$2.51	N/A	N/A	N/A	N/A	-56.28%	-44.76%	N/A

Latest SCNX, MNOV, DWTX, and HRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	DWTX Dogwood Therapeutics	-$0.14	-$0.34	-$0.20	-$0.34	N/A	N/A
8/13/2026	Q2 2026	MNOV MediciNova	-$0.0633	-$0.05	+$0.0133	-$0.05	$0.08 million	$0.46 million
8/13/2026	Q2 2026	SCNX Scienture	-$0.09	-$0.07	+$0.02	-$0.07	$1.96 million	$0.34 million
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.0050	-$0.03	-$0.0250	-$0.03	$42.19 million	$37.67 million
5/15/2026	Q1 2026	SCNX Scienture	-$0.23	-$0.08	+$0.15	-$0.08	$0.40 million	$0.06 million
5/14/2026	Q1 2026	DWTX Dogwood Therapeutics	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
5/14/2026	Q1 2026	MNOV MediciNova	-$0.06	-$0.05	+$0.01	-$0.05	$0.19 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DWTX Dogwood Therapeutics	N/A	5.86	5.86
HRTX Heron Therapeutics	17.51	2.53	1.51
MNOV MediciNova	N/A	9.09	9.09
SCNX Scienture	N/A	1.70	1.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DWTX Dogwood Therapeutics	9.05%
HRTX Heron Therapeutics	80.01%
MNOV MediciNova	9.90%
SCNX Scienture	5.68%

Insider Ownership

Company	Insider Ownership
DWTX Dogwood Therapeutics	0.30%
HRTX Heron Therapeutics	6.10%
MNOV MediciNova	14.00%
SCNX Scienture	21.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DWTX Dogwood Therapeutics	5	33.63 million	33.53 million	N/A
HRTX Heron Therapeutics	300	189.85 million	178.27 million	Optionable
MNOV MediciNova	10	49.22 million	42.33 million	Optionable
SCNX Scienture	N/A	40.63 million	31.94 million	N/A

SCNX, MNOV, DWTX, and HRTX Headlines

Recent News About These Companies

Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses

August 14 at 8:31 AM | quiverquant.comQ

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

August 14 at 8:08 AM | globenewswire.com

Scienture Holdings Stock Price History

August 12 at 6:43 PM | investing.com

Scienture launches Rezenopy as second FDA-approved commercial product

August 12 at 6:43 PM | msn.com

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

August 12 at 8:05 AM | globenewswire.com

Scienture Holdings纳洛酮鼻喷雾剂7月将向美批发商发货

July 28, 2026 | finance.sina.com.cnF

Scienture Holdings stock jumps over 20% pre-market: Here's why

July 10, 2026 | msn.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | finance.yahoo.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | globenewswire.com

SCNX Share News Today

July 4, 2026 | uk.investing.com

Scienture Holdings (SCNX) Stock Forecast & Price Target

June 25, 2026 | investing.com

Scienture Holdings Stock Short Interest Report | NASDAQ:SCNX | Benzinga

June 24, 2026 | benzinga.com

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

June 18, 2026 | globenewswire.com

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)

June 17, 2026 | theglobeandmail.com

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

June 9, 2026 | globenewswire.com

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

June 4, 2026 | accessnewswire.comA

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

June 2, 2026 | globenewswire.com

Scienture Holdings Announces CFO Resignation, Names Interim Successor

May 29, 2026 | tipranks.com

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

May 18, 2026 | globenewswire.com

Scienture Holdings Inc SCNX

May 12, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, MNOV, DWTX, and HRTX Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

$2.15 +0.17 (+8.59%)

Closing price 04:00 PM Eastern

Extended Trading

$2.02 -0.13 (-6.09%)

As of 07:59 PM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Heron Therapeutics NASDAQ:HRTX

$0.34 +0.00 (+0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$0.35 +0.01 (+3.06%)

As of 07:34 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

MediciNova NASDAQ:MNOV

$1.31 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.30 -0.01 (-0.38%)

As of 04:10 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Scienture NASDAQ:SCNX

$0.47 +0.00 (+0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$0.46 0.00 (-1.05%)

As of 07:59 PM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCNX, MNOV, DWTX, and HRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCNX, MNOV, DWTX, and HRTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCNX, MNOV, DWTX, and HRTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, MNOV, DWTX, and HRTX Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

Heron Therapeutics NASDAQ:HRTX

MediciNova NASDAQ:MNOV

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCNX, MNOV, DWTX, and HRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCNX, MNOV, DWTX, and HRTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCNX, MNOV, DWTX, and HRTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, MNOV, DWTX, and HRTX Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

Heron Therapeutics NASDAQ:HRTX

MediciNova NASDAQ:MNOV

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools